Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use RYZNEUTA ®safely and effectively. See full prescribing information for RYZNEUTA. RYZNEUTA ®(efbemalenograstim alfa-vuxw) injection, for subcutaneous use Initial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-prescription
RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Limitations of Use RYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
- generic_name
- efbemalenograstim alfa-vuxw
- product_names
- efbemalenograstim alfa-vuxw
- ndc
- 72893-016, 72893-016-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en